In vivo RNAi screen and validation reveals Ngp, Hba-a1, and S100a8 as novel inhibitory targets on T lymphocytes in liver cancer

In vivo RNAi screen and validation reveals Ngp, Hba-a1, and S100a8 as novel inhibitory targets on T lymphocytes in liver cancer

BackgroundHepatocellular carcinoma (HCC) represents the third deadliest cancer worldwide with limited treatment options. Immune checkpoint inhibitors (ICIs) have revolutionized HCC therapy, but immune suppression within the tumor microenvironment remains a major challenge. Therefore, in this study,...

Full description

Saved in:
Bibliographic Details
Main Authors: Inga Hochnadel, Lisa Hoenicke, Nataliia Petriv, Huizhen Suo, Lothar Groebe, Chantal Olijnik, Nina Bondarenko, Juan C. Alfonso, Michael Jarek, Ruibing Shi, Andreas Jeron, Kai Timrott, Tatjana Hirsch, Nils Jedicke, Dunja Bruder, Frank Klawonn, Ralf Lichtinghagen, Robert Geffers, Henrike Lenzen, Michael P. Manns, Tetyana Yevsa
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-04-01
Series:Frontiers in Immunology
Subjects:
RNA interference screen
T lymphocytes
hepatocellular carcinoma
immunotherapy
immune checkpoint inhibitors
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2025.1549229/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2025.1549229/full

Similar Items